{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:11:55Z","timestamp":1783977115592,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoetic stem cell transplantation (allo SCT) is a treatment option with a unique chance of cure for patients with high-risk AML or MDS. However, the optimal path for an individual patient on its way to allo SCT is far from clear and subject of ongoing debates. Upfront transplantation \u201cas soon as possible\u201d competes with strategies to achieve deep remission or at least stabilization of the disease. In this context, we performed a survey among German transplant centers to assess their preferred strategies for patients before SCT in five typical scenarios of AML and MDS. We obtained replies from 22 centers, revealing a heterogenous use of possible strategies. Upfront transplantation was a preferred option (68%) in intermediate risk MDS, chemotherapy was preferred (64%) as bridging for AML in remission, whereas hypomethylating agents (HMA) and induction chemotherapy for relapsed AML were highly controversial. Further prospective evaluation of different options is desirable.<\/jats:p>","DOI":"10.1007\/s00277-026-07115-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:23:46Z","timestamp":1780701826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-4651","authenticated-orcid":false,"given":"Stefan W.","family":"Krause","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Elmaagacli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz P.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"9","key":"7115_CR1","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29(9):1190\u20131197. https:\/\/doi.org\/10.1200\/JCO.2010.31.8121","journal-title":"J Clin Oncol"},{"issue":"5","key":"7115_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102(5):865\u2013873. https:\/\/doi.org\/10.3324\/haematol.2016.159343","journal-title":"Haematologica"},{"issue":"5","key":"7115_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2017.02.006","volume":"23","author":"D Weber","year":"2017","unstructured":"Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J, Dettmer K, Weber M, Wolff D, Hahn J, Pamer EG, Herr W, Gessner A, Oefner PJ, van den Brink MRM, Holler E (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl 23(5):845\u2013852. https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.006","journal-title":"Biol Blood Marrow Transpl"},{"key":"7115_CR4","doi-asserted-by":"publisher","unstructured":"Pollyea D (2017) The case for abandoning induction chemotherapy. The Hematologist 14(3). https:\/\/doi.org\/10.1182\/hem.V14.3.7298","DOI":"10.1182\/hem.V14.3.7298"},{"key":"7115_CR5","doi-asserted-by":"publisher","unstructured":"Rautenberg C, Bergmann A, Germing U, Fischermanns C, Pechtel S, Kaivers J, Jager P, Schuler E, Haas R, Kobbe G, Schroeder T (2020) Prediction of response and survival following treatment with azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation. Cancers (Basel) 12(8). https:\/\/doi.org\/10.3390\/cancers12082255","DOI":"10.3390\/cancers12082255"},{"key":"7115_CR6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028730","author":"M Stelljes","year":"2025","unstructured":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Mueller LP, Schmid C, Krause SW, Bethge WA, Jost E, Platzbecker U, Klein S, Niederland J, Kaufmann M, Schafer-Eckart K, Baldauf H, Stolzel F, Trost S, Rollig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornhauser M, Schetelig J (2025) Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. Blood. https:\/\/doi.org\/10.1182\/blood.2025028730","journal-title":"Blood"},{"issue":"3","key":"7115_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","volume":"112","author":"EP Alessandrino","year":"2008","unstructured":"Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A, Gruppo Italiano Trapianto di Midollo O (2008) WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112(3):895\u2013902. https:\/\/doi.org\/10.1182\/blood-2008-03-143735","journal-title":"Blood"},{"issue":"36","key":"7115_CR8","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","volume":"30","author":"G Damaj","year":"2012","unstructured":"Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 30(36):4533\u20134540. https:\/\/doi.org\/10.1200\/JCO.2012.44.3499","journal-title":"J Clin Oncol"},{"issue":"30","key":"7115_CR9","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kroger","year":"2021","unstructured":"Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schafer-Eckart K, Scheid C, Nolte F, Kronke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U (2021) Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol 39(30):3318\u20133327. https:\/\/doi.org\/10.1200\/JCO.20.02724","journal-title":"J Clin Oncol"},{"issue":"3","key":"7115_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/sj.leu.2403640","volume":"19","author":"K Nakai","year":"2005","unstructured":"Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M, Kato S (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19(3):396\u2013401. https:\/\/doi.org\/10.1038\/sj.leu.2403640","journal-title":"Leukemia"},{"issue":"9","key":"7115_CR11","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41409-024-02365-5","volume":"59","author":"JC Schroeder","year":"2024","unstructured":"Schroeder JC, Mix L, Faustmann P, Weller JF, Fehn A, Phely L, Riedel A, Vogel W, Faul C, Lengerke C, Bethge WA (2024) Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome. Bone Marrow Transpl 59(9):1332\u20131334. https:\/\/doi.org\/10.1038\/s41409-024-02365-5","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"7115_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3324\/haematol.2015.140996","volume":"101","author":"C Craddock","year":"2016","unstructured":"Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kroger N, Nagler A, Mohty M (2016) Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 101(7):879\u2013883. https:\/\/doi.org\/10.3324\/haematol.2015.140996","journal-title":"Haematologica"},{"issue":"8","key":"7115_CR13","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","volume":"25","author":"T Schroeder","year":"2019","unstructured":"Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, Kondakci M, Haas R, Germing U, Kobbe G (2019) Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. Biol Blood Marrow Transpl 25(8):1550\u20131559. https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"7115_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDSSSG (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223\u2013232. https:\/\/doi.org\/10.1016\/S1470-2045(09)70003-8","journal-title":"Lancet Oncol"},{"issue":"7","key":"7115_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"2","key":"7115_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2024013086","volume":"9","author":"JM Unglaub","year":"2025","unstructured":"Unglaub JM, Schlenk RF, Middeke JM, Krause SW, Kraus S, Einsele H, Kramer M, Zukunft S, Kauer J, Renders S, Katelari E, Schliemann C, Pabst C, Luft T, Dreger P, Rollig C, Bornhauser M, Muller-Tidow C, Sauer T (2025) Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed\/refractory AML. Blood Adv 9(2):375\u2013385. https:\/\/doi.org\/10.1182\/bloodadvances.2024013086","journal-title":"Blood Adv"},{"issue":"4","key":"7115_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","volume":"39","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM (2025) Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854\u2013863. https:\/\/doi.org\/10.1038\/s41375-025-02531-8","journal-title":"Leukemia"},{"key":"7115_CR18","doi-asserted-by":"publisher","unstructured":"Ruhnke L (2023) Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage treatment for relapsed\/refractory AML: updated results of the Phase-I\/II SAL Relax Trial. Blood 142. https:\/\/doi.org\/10.1182\/blood-2023-184445","DOI":"10.1182\/blood-2023-184445"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07115-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07115-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07115-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:02:05Z","timestamp":1783976525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07115-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7115"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07115-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8433675\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No research on human subjects or animals was performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"AE: None. GB: Speaker\u00b4s honoraria: Abbvie, Gilead, Jazz, Medac; Advisory Board: BMS, Jazz, Novartis, Sanofi; Travel support: Gilead, Jazz, Sanofi. WB: Consultancy and Honoraria: AbbVie, BMS, Gilead, Janssen and Novartis. EJ: Honoraria: JAZZ, Travel support: Medac, Neovii. GK: Advisory Role or Speaker Honoraria: MSD, Pfizer, Amgen, Novartis, Gilead, BMS-Celgene, Abbvie, Biotest, Takeda, Eurocept, Sanofi. Financing of Scientific Research: BMS-Celgene, Amgen, Abbvie, Eurocept, Medac. SAK: none. SK: none. SWK: Honoraria: Eickeler. Travel support: Jazz, Alexion, Abbvie. WHK: none. TL: None. LPM: Advisory Role or Expert Testimony: Pfizer, Gilead, Novartis, Amgen; Honoraria \/ Travel grants: AbbVie, Bristol-Myers Squibb, Gilead, Sanofi-Aventis; Financing of Scientific Research Amgen . CR: Consultancy und Honoraria: AbbVie Inc., Amgen, Astellas, Bristol-Meyer-Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, J&J, Novartis, Otsuka, Pfizer, Roche, Servier; Research Funding: AbbVie Inc., Astellas, Novartis, Pfizer. JS: consultancy: BMS, Janssen, MSD, and Sanofi. Lecture Fees: Astellas, Novartis, Jazz, Eurocept, Medac, Janssen. MS: consultancy for Pfizer, MSD, Bristol-Myers Squibb (BMS), Incyte, Takeda, Astellas, Autolus, Sanofi, Amgen; speaker for Pfizer, Medac, MSD, Astellas, Jazz Pharmaceuticals, Amgen, Novartis, Gilead, Celgene, BMS, AbbVie, Incyte; research funding from Pfizer; travel support from Medac, Sanofi, Pfizer KSE: None. NS: None. JT: None. DW: Research Grant from Novartis, Honoraria from Novartis, Sanofi, Incyte, Neovii . FW: None. JW: none.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}